Scarica l'app Stockscreener
0.38
0.41%
-0.0008
Precedente Chiudi:
$0.3808
Aprire:
$0.3636
Volume 24 ore:
1.70M
Relative Volume:
0.87
Capitalizzazione di mercato:
$31.82M
Reddito:
$1.22M
Utile/perdita netta:
$-14.15M
Rapporto P/E:
-1.4615
EPS:
-0.26
Flusso di cassa netto:
$-6.55M
1 W Prestazione:
+19.52%
1M Prestazione:
+26.42%
6M Prestazione:
+16.30%
1 anno Prestazione:
-14.60%
Intervallo 1D:
$0.361
$0.3822
Intervallo di 1 settimana:
$0.3165
$0.461
Portata 52W:
$0.2525
$0.498
IGC Pharma Inc Stock (IGC) Company Profile
Nome
IGC Pharma Inc
Settore
Industria
Telefono
301-983-0998
Indirizzo
4336 Montgomery Avenue, Bethesda, MD
Confronta IGC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3792 | 26.62M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.00 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.47 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.82 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.37 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
IGC Pharma Inc Borsa (IGC) Ultime notizie
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection - ACCESS Newswire
New AI Breakthrough Could Detect Alzheimer's Years Before Symptoms: 400M People Could Benefit - Stock Titan
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
The IGC Stock Puzzle: Unraveling IGC Pharma Inc’s Fluctuating Performance - investchronicle.com
IGC Pharma Stock Soars 57.92% on Partnership, Sustainability - AInvest
Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Here's Why - Benzinga
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates - MSN
IGC Pharma Reports Transformative Year in Alzheimer’s Innovation - TipRanks
IGC Pharma: Fiscal Year 2025 Financial and Operational HighlightsA Year of Transformative Progress in Alzheimer's Innovation | IGC Stock News - GuruFocus
Earnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - ACCESS Newswire
IGC Pharma Full Year 2025 Results: Key Financial Updates Coming June 30What to Watch - Stock Titan
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - ACCESS Newswire
IGC Pharma Expands Alzheimer's Dementia Agitation Treatment Trial to Yukon - MarketScreener
IGC Pharma Highlights Alzheimer’s Research Progress - TipRanks
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - sharewise
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Sto - GuruFocus
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market - ACCESS Newswire
IGC Pharma Targets Puerto Rico's 12.5% Alzheimer's Rate in Strategic Trial Expansion - Stock Titan
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Oppor - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC - GuruFocus
IGCPharma (IGC) Confirms Genetic Safety of Alzheimer's Drug Ingr - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
Is IGC Pharma Inc (IGC) a good investment opportunity? - uspostnews.com
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Welcomes Strategic Investment from Advisors - PharmiWeb.com
IGC Pharma (IGC) Secures $475K Investment to Advance Alzheimer's Trial | IGC Stock News - GuruFocus
IGC Pharma Welcomes Strategic Investment from Advisors | IGC Sto - GuruFocus
IGC Pharma Welcomes Strategic Investment From Advisors - Barchart.com
The 7 Best Stocks Under 50 Cents To Buy For July 2025! - The Stock Dork
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporti - GuruFocus
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | IGC Stock News - GuruFocus
Former MassBio CEO Joins IGC Pharma's Advisory Board to Advance AI-Powered Alzheimer's Programs - Stock Titan
India Globalization Capital : IGC Announces Results of its 2020 Annual Stockholders Meeting - marketscreener.com
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - marketscreener.com
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Newswire.com
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital - PharmiWeb.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - BioSpace
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma Accelerates Alzheimer's Breakthrough: Key Research Center Joins Phase 2 Trial - Stock Titan
IGC Pharma Inc Azioni (IGC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):